MET as a target in papillary renal cell carcinoma
- PMID: 24812413
- DOI: 10.1158/1078-0432.CCR-14-0690
MET as a target in papillary renal cell carcinoma
Abstract
The biology underlying papillary renal cell carcinoma (pRCC) is largely unknown, and no specific therapies have been developed for advanced disease. The elucidation of the MET pathway status in types I and II pRCC may help to select patients who are more likely to benefit from MET inhibitors.
©2014 American Association for Cancer Research.
Comment on
-
MET is a potential target across all papillary renal cell carcinomas: result from a large molecular study of pRCC with CGH array and matching gene expression array.Clin Cancer Res. 2014 Jul 1;20(13):3411-21. doi: 10.1158/1078-0432.CCR-13-2173. Epub 2014 Mar 21. Clin Cancer Res. 2014. PMID: 24658158
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
